Pharma GCC pay is moving for a reason IT isn’t
While IT and BFSI bands have steadied, senior pharma roles are climbing. The driver is regulatory-side, not technology-side.
Draft. Figures marked like this are illustrative and pending verification against Recruise placement data & Sachith sign-off before publication.
Key takeaways
- While IT and BFSI senior bands have steadied, senior pharma GCC roles are still climbing — and for a different reason.
- The driver is regulatory-side, not technology-side: scarcity of people who can carry compliance-grade accountability, not a tooling race.
- Benchmarks built on a tech-GCC basket systematically under-price the pharma roles that matter most.
Two segments, two engines — and only one of them is cooling.
The tidy story of the moment is that senior GCC pay has stabilised. In IT and BFSI, our own closes mostly agree. But run the same read across senior pharma roles and the line is still rising. The temptation is to explain it with the same forces — an AI premium, a platform race — and that explanation is wrong. The pharma driver isn’t technology-side at all.
It’s regulatory. The seats commanding the premium are the ones that carry compliance-grade accountability: pharmacovigilance leadership, regulatory affairs, quality and validation, clinical-data governance. These are roles where a mis-hire isn’t merely expensive — it’s a finding, an audit, a submission at risk. The people who can hold that responsibility, at scale, from an offshore centre, are genuinely scarce, and the price reflects it.
“IT pay is cooling because supply caught up. Pharma pay isn’t, because you can’t train your way to a regulator’s trust in a hiring cycle. That scarcity doesn’t ease on the same clock.”
Sachith Rai · MD & Founder, Recruise
Why a tech-weighted benchmark quietly under-prices you.
Most published India-GCC benchmarks are dominated by technology roles — that’s where the volume is. When a pharma centre sets a regulatory-leadership band from that basket, it inherits a distribution shaped by a segment whose scarcity works differently. The result is a number that looks defensible and lands a rung or two under where the actual candidates are being courted.
The correction is to benchmark the seat, not the sector: price regulatory-side pharma roles against the narrow pool that can actually fill them, and treat the broad GCC survey as background, not basis. The scarcity is real and role-specific. Pay that averages it away loses exactly the hires that a pharma GCC can least afford to miss.
One pattern worth knowing, every week.
The Signal is our weekly read on the senior GCC talent market — one chart, one pattern, no noise. Written from live placement data.
More from Recruise Insights.
The AI/ML salary band just snapped in two
The top of band hasn't moved — it has split. Two markets now operate side by side, and most benchmarks still price them as one.
The hidden cost of paying at the 75th percentile
It sounds defensible. It’s also why your offer-accept rate is slipping. The real benchmark isn’t where you think.
The published band and the closed offer are two different numbers
One is written by people not running mandates. The other is what the candidate actually signs. Only one of them should set your budget.